for people ages 18 years and up (full criteria)
study started
completion around



Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.

Official Title

Aveir Dual-Chamber Leadless i2i IDE Study


The purpose of this clinical investigation is to evaluate the clinical safety and effectiveness of the Aveir DR Leadless Pacemaker system in a patient population indicated for a DDD(R) pacemaker.

Subjects participating in the study are followed through at least 12 months with data collected at baseline, implant procedure, pre (hospital) discharge, and follow-up at 1 month, 3 months, 6 months, 12 months, and every 6 months thereafter until study completion


Cardiac Pacemaker, Artificial, Cardiac Rhythm Disorder, Bradycardia, Sick Sinus Syndrome, Pacemaker, AV Block, Vasovagal Syncope, Cardiac Arrhythmias, Aveir DR Leadless Pacemaker System


You can join if…

Open to people ages 18 years and up

  1. Subject must have at least one of the clinical indications before device implant in adherence with ACC/AHA/HRS/ESC dual chamber pacing guidelines
  2. Subject is ≥ 18 years of age or age of legal consent, whichever age is greater
  3. Subject has a life expectancy of at least one year
  4. Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams
  5. Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC

You CAN'T join if...

  1. Subject is currently participating in another clinical investigation that may confound the results of this study as determined by the Sponsor
  2. Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period
  3. Subject has presence of anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could confound the assessment of the investigational device and/or implant procedure, limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements of the clinical investigation results
  4. Subject has a known allergy or hypersensitivity to < 1 mg of dexamethasone sodium phosphate or any blood or tissue contacting material listed in the IFU
  5. Subject has an implanted vena cava filter or mechanical tricuspid valve prosthesis
  6. Subject has pre-existing, permanent endocardial pacing or defibrillation leads (does not include lead fragments)
  7. Subject has current implantation of either conventional or subcutaneous implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device
  8. Subject has an implanted leadless cardiac pacemaker (except for an Aveir ventricular leadless pacemaker)
  9. Subject is implanted with an electrically-active implantable medical device with stimulation capabilities (such as neurological or cardiac stimulators)

    10. Subject is unable to read or write


  • University of California at San Diego (UCSD) Medical Center
    San Diego California 92118-8411 United States
  • Pacific Heart Institute
    Santa Monica California 90404 United States
  • Cedars-Sinai Medical Center
    Los Angeles California 90048 United States
  • Premier Cardiology, Inc
    Newport Beach California 92663 United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles California 90027 United States
  • Providence Medical Foundation
    Orange California 92868 United States
  • USC University Hospital
    Los Angeles California 90033 United States
  • Huntington Memorial Hospital
    Pasadena California 91105 United States


in progress, not accepting new patients
Start Date
Completion Date
Abbott Medical Devices
Study Type
About 500 people participating
Last Updated